Switching from insulin to GLP-1/GIP receptor agonists (e.g., tirzepatide) may benefit patients with type 2 diabetes, especially those needing weight loss, better glycemic control, or reduced hypoglycemia. Here, GLP1R is linked to type 2 diabetes mellitus.